These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 39022993

  • 1. Association of personalized and tumor-informed ctDNA with patient survival outcomes in pancreatic adenocarcinoma.
    Botta GP, Abdelrahim M, Drengler RL, Aushev VN, Esmail A, Laliotis G, Brewer CM, George GV, Abbate SM, Chandana SR, Tejani MA, Malla M, Bansal D, Rivero-Hinojosa S, Spickard E, McCormick N, Cecchini M, Lacy J, Fei N, Kasi PM, Kasi A, Dayyani F, Hanna DL, Sharma S, Malhotra M, Aleshin A, Liu MC, Jurdi A.
    Oncologist; 2024 Oct 03; 29(10):859-869. PubMed ID: 39022993
    [Abstract] [Full Text] [Related]

  • 2. Mutant KRAS Circulating Tumor DNA Is an Accurate Tool for Pancreatic Cancer Monitoring.
    Perets R, Greenberg O, Shentzer T, Semenisty V, Epelbaum R, Bick T, Sarji S, Ben-Izhak O, Sabo E, Hershkovitz D.
    Oncologist; 2018 May 03; 23(5):566-572. PubMed ID: 29371474
    [Abstract] [Full Text] [Related]

  • 3. Initial Report: Personalized Circulating Tumor DNA and Survival in Patients with Resectable Pancreatic Cancer.
    Eckhoff AM, Kanu E, Fletcher A, Bao M, Aushev VN, Spickard E, Nussbaum DP, Allen PJ.
    Ann Surg Oncol; 2024 Mar 03; 31(3):1444-1446. PubMed ID: 38170407
    [Abstract] [Full Text] [Related]

  • 4. Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer.
    Patel H, Okamura R, Fanta P, Patel C, Lanman RB, Raymond VM, Kato S, Kurzrock R.
    J Hematol Oncol; 2019 Dec 04; 12(1):130. PubMed ID: 31801585
    [Abstract] [Full Text] [Related]

  • 5. Prognostic impact of circulating tumor DNA detection in portal and peripheral blood in resected pancreatic ductal adenocarcinoma patients.
    Maulat C, Canivet C, Cabarrou B, Pradines A, Selves J, Casanova A, Doussine A, Hanoun N, Cuellar E, Boulard P, Carrère N, Buscail L, Bournet B, Muscari F, Cordelier P.
    Sci Rep; 2024 Nov 08; 14(1):27296. PubMed ID: 39516243
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Prognostic utility of preoperative and postoperative KRAS-mutated circulating tumor DNA (ctDNA) in resected pancreatic ductal adenocarcinoma: A systematic review and meta-analysis.
    Alqahtani A, Alloghbi A, Coffin P, Yin C, Mukherji R, Weinberg BA.
    Surg Oncol; 2023 Dec 08; 51():102007. PubMed ID: 37852124
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Circulating tumor DNA as a prognostic indicator in resectable pancreatic ductal adenocarcinoma: A systematic review and meta-analysis.
    Lee JS, Rhee TM, Pietrasz D, Bachet JB, Laurent-Puig P, Kong SY, Takai E, Yachida S, Shibata T, Lee JW, Park HC, Zang DY, Jeon K, Lee J, Kim M, Kim HS, Kang HJ, Lee YK.
    Sci Rep; 2019 Nov 18; 9(1):16971. PubMed ID: 31740696
    [Abstract] [Full Text] [Related]

  • 12. New Biomarkers to Define a Biological Borderline Situation for Pancreatic Adenocarcinoma: Results of an Ancillary Study of the PANACHE01-PRODIGE48 Trial.
    Pinson J, Henriques J, Beaussire L, Sarafan-Vasseur N, Sa Cunha A, Bachet JB, Vernerey D, Di Fiore F, Schwarz L, PANACHE01-PRODIGE48 group.
    Ann Surg; 2024 Nov 01; 280(5):734-744. PubMed ID: 39101207
    [Abstract] [Full Text] [Related]

  • 13. Circulating tumor DNA quantity is related to tumor volume and both predict survival in metastatic pancreatic ductal adenocarcinoma.
    Strijker M, Soer EC, de Pastena M, Creemers A, Balduzzi A, Beagan JJ, Busch OR, van Delden OM, Halfwerk H, van Hooft JE, van Lienden KP, Marchegiani G, Meijer SL, van Noesel CJ, Reinten RJ, Roos E, Schokker S, Verheij J, van de Vijver MJ, Waasdorp C, Wilmink JW, Ylstra B, Besselink MG, Bijlsma MF, Dijk F, van Laarhoven HW.
    Int J Cancer; 2020 Mar 01; 146(5):1445-1456. PubMed ID: 31340061
    [Abstract] [Full Text] [Related]

  • 14. Prognostic impact of postoperative circulating tumor DNA as a molecular minimal residual disease marker in patients with pancreatic cancer undergoing surgical resection.
    Hata T, Mizuma M, Motoi F, Ohtsuka H, Nakagawa K, Morikawa T, Unno M.
    J Hepatobiliary Pancreat Sci; 2023 Jun 01; 30(6):815-824. PubMed ID: 36408698
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer.
    Tarazona N, Gimeno-Valiente F, Gambardella V, Zuñiga S, Rentero-Garrido P, Huerta M, Roselló S, Martinez-Ciarpaglini C, Carbonell-Asins JA, Carrasco F, Ferrer-Martínez A, Bruixola G, Fleitas T, Martín J, Tébar-Martínez R, Moro D, Castillo J, Espí A, Roda D, Cervantes A.
    Ann Oncol; 2019 Nov 01; 30(11):1804-1812. PubMed ID: 31562764
    [Abstract] [Full Text] [Related]

  • 17. Circulating Tumor DNA as a Sensitive Marker in Patients Undergoing Irreversible Electroporation for Pancreatic Cancer.
    Lin M, Alnaggar M, Liang S, Chen J, Xu K, Dong S, Du D, Niu L.
    Cell Physiol Biochem; 2018 Nov 01; 47(4):1556-1564. PubMed ID: 29940591
    [Abstract] [Full Text] [Related]

  • 18. Improved Assessment of Response Status in Patients with Pancreatic Cancer Treated with Neoadjuvant Therapy using Somatic Mutations and Liquid Biopsy Analysis.
    Yin L, Pu N, Thompson E, Miao Y, Wolfgang C, Yu J.
    Clin Cancer Res; 2021 Feb 01; 27(3):740-748. PubMed ID: 33082211
    [Abstract] [Full Text] [Related]

  • 19. Personalized, tumor-informed, circulating tumor DNA assay for detecting minimal residual disease in non-small cell lung cancer patients receiving curative treatments.
    Oh Y, Yoon SM, Lee J, Park JH, Lee S, Hong T, Chung LI, Sudhaman S, Riddell T, Palsuledesai CC, Krainock M, Liu MC, Chae YK.
    Thorac Cancer; 2024 May 01; 15(13):1095-1102. PubMed ID: 38558374
    [Abstract] [Full Text] [Related]

  • 20. Longitudinal analysis of cell-free mutated KRAS and CA 19-9 predicts survival following curative resection of pancreatic cancer.
    Hussung S, Akhoundova D, Hipp J, Follo M, Klar RFU, Philipp U, Scherer F, von Bubnoff N, Duyster J, Boerries M, Wittel U, Fritsch RM.
    BMC Cancer; 2021 Jan 11; 21(1):49. PubMed ID: 33430810
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.